Overview

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
A dose finding study in locally advanced and/or metastatic pancreatic cancer patients
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Everolimus
Gemcitabine
Sirolimus